Granules India is currently trading at Rs. 95.30, up by 0.65 points or 0.69% from its previous closing of Rs. 94.65 on the BSE.
The scrip opened at Rs. 94.00 and has touched a high and low of Rs. 95.75 and Rs. 92.90 respectively. So far 1,11,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 157.00 on 18-May-2017 and a 52 week low of Rs. 91.30 on 14-May-2018.
Last one week high and low of the scrip stood at Rs. 101.50 and Rs. 91.30 respectively. The current market cap of the company is Rs. 2,419.00 crore.
The promoters holding in the company stood at 44.94%, while Institutions and Non-Institutions held 17.55% and 37.51% respectively.
The US Food and Drug Administration (USFDA) has issued Establishment Inspection Report (EIR) for Granules India’s Jeedimetla facility located at Hyderabad, Telangana, India. This facility was inspected by USFDA in March 2018 and there was one (1) 483 observation during the inspection. The company has responded to the observation within the stipulated timeframe. Jeedimetla facility manufactures Active pharmaceutical ingredients (APIs) and Pharmaceutical Formulation Intermediates (PFIs).
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
